Adaptation and clinical evaluation of a homogenous enzyme multiplied immunoassay technique (EMIT) for drug monitoring of a methotrexate-albumin conjugate (MTX-HSA) in humans

Onkologie

Volumn 23, Issue 4, 2000, Pages 352-357

  Hartung, G ^a   Heeger, S ^a   Bertsch, T ^a   Frei, E ^b   Wunder, A ^b   Kranzle M ^a   Stehle, G ^a   Weigand, M ^b   Schrenk, H H ^b   Sinn, H ^b   Queisser W ^a  

^a UNIVERSITY OF HEIDELBERG   (Germany)

^b GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

Author keywords

7 Hydroxymethotrexate; Albumin conjugates; Drug carriers; EMIT; Methotrexate pharmacology

Indexed keywords

7 HYDROXYMETHOTREXATE; ALBUMIN CONJUGATE; METHOTREXATE;

ACCURACY; ARTICLE; CALIBRATION; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG DETERMINATION; DRUG MONITORING; ENZYME MULTIPLIED IMMUNOASSAY TECHNIQUE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; QUALITY CONTROL; STANDARDIZATION;

EID: 0033832206     PISSN: 0378584X     EISSN: None     Source Type: Journal    
DOI: 10.1159/000027169     Document Type: Article

References (27)

1. Seeger DR, Cosulich DB, Smith JM, Hultquist ME: Analogs of pteroyl glutamic acid. III. 4 Amino derivatives. J Am Chem Soc 1949;71:1753-1755.
2. Hertz R, Lewis J, Lipsett MB: Five years experience with the chemotherapy of metastatic choriocarcinoma and related trophoblastic tumors in women. Am J Obstet Gynecol 1961;82:631-637.
3. Bertino JR: Ode to methotrexate. J Clin Oncol 1993; 11:5-14.
4. Kaye SB: New antimetabolites in cancer chemotherapy and their clinical impact. Br J Cancer 1998; 78(suppl 3):1-7.
5. Chabner BA: Anticancer drugs; in de Vita VT, Hellman S, Rosenberg SA (eds): Cancer: Principles and Practice of Oncology. Philadelphia, Lippincott, 1993, pp 325-417.
6. Evans WE, Crom WR, Yalowich JC: Methotrexate; in Evans WE, Schentag JJ, Jusko WJ, Harrison H (eds): Applied Pharmacokinetics: Principles of Therapeutic Drug Monitoring. Spokane, WA, Applied Therapeutics, 1986, pp 1009-1056.
7. Friberg S, Mattson S: On the growth rates of human malignant tumors: Implications for medical decision making. J Surg Oncol 1997;65:284-297.
8. Hartung G, Stehle G, Sinn H, Wunder A, Schrenk HH, Heeger S, Kränzle M, Edler L, Frei E, Fiebig HH, Heene DL, Maier-Borst W, Queißer W: Phase I trial of Methotrexate-Albumin in a weekly intravenous bolus regimen in cancer patients. Clin Cancer Res 1999;5:753-759.
9. Peters T: All about albumin: Biochemistry, genetics and medical applications. San Diego, Academic Press, 1996.
10. Stehle G, Sinn H, Wunder A, Schrenk HH, Stewart JCM, Hartung G, Maier-Borst W, Heene DL: Plasma protein (albumin) catabolism by the tumor itself -implications for tumor metabolism and the genesis of cachexia. Crit Rev Oncol Hematol 1997;26: 77-100.
11. Andersson C, Iresjo BM, Lundholm K: Identification of tissue sites for increased albumin degradation in sarcoma-bearing mice. J Surg Res 1991;50:156-162.
12. Sinn H, Schrenk HH, Friedrich EA, Schilling U, Maier-Borst W: Design of compounds having enhanced tumor uptake, using serum albumin as a carrier. Part I. Int J Rad Appl Instrum 1990;17:819-827.
13. Wunder A, Stehle G, Sinn H, Schrenk HH, Hoff-Biederbeck D, Bader F, Friedrich EA, Peschke P, Maier-Borst W, Heene DL: Enhanced albumin uptake by rat tumors. Int J Oncol 1997;11:497-507.
14. Stehle G, Sinn H, Wunder A, Schrenk HH, Schütt S, Heene DL, Maier-Borst W: The loading rate determines tumor targeting of methotrexate-albumin conjugates in rats. Anticancer Drugs 1997;8:677-685.
15. Stehle G, Wunder A, Sinn H, Schrenk HH, Schutt S, Frei E, Hartung G, Maier-Borst W, Heene DL: Pharmacokinetics of methotrexate-albumin conjugates in tumor bearing rats. Anticancer Drugs 1997;8:835-844.
16. Wunder A, Stehle G, Schrenk HH, Hartung G, Heene DL, Maier-Borst W, Sinn H: Antitumor activity of methotrexate-albumin conjugates in rats bearing a Walker-256 carcinosarcoma. Int J Cancer 1998;76:884-890.
17. Stehle G, Wunder A, Schrenk HH, Hartung G, Heene DL, Sinn H: Methotrexate-albumin conjugate causes tumor growth delay in Dunning R3327 Hi prostate cancer bearing rats. Anticancer Drugs 1999;10:405-411.
18. Fiebig HH, Roth T, Hartung G, Sinn H, Stehle G: In vivo activity of a methotrexate-albumin conjugate (MTX-HSA) in human tumor xenografts. Eur J Cancer 1997;33(suppl 8):S174(abstract).
19. Hartung G, Stehle G, Heeger S, Kranzle M, Wunder A, Bertsch T, Köpke J, Spacek S, Sinn H, Queißer W: Drug monitoring and pharmacokinetics of a methotrexate-albumin conjugate (MTX-HSA) in cancer patients with long term remission. Eur J Cancer 1999;35(suppl 4):1188(abstract).
20. Oellerich M, Engelhardt P, Schaadt M, Diehl V: Determination of methotrexate in serum by a rapid, fully mechanized enzyme immunoassay (EMIT). J Clin Chem Clin Biochem 1980;18:169-174.
21. Paxton JW, Rosw ell FJ: A rapid, sensitive and specific radioimmunoassay for methotrexate. Clin Chim Acta 1977;80:563-572.
22. Finley PR, Williams RJ: Methotrexate assay by enzymatic inhibition, with use of the centrifugal analyzer. Clin Chem 1977;23:2139-2141.
23. Schalhora A, Wilmanns W, Stupp-Poutot G: Methotrexat-Nachweis im menschlichen Serum - Vergleich zwischen einer enzymatischen und einer enzymimmunologischen Methode. Onkologie 1980;4:193-196.
24. Nelson JA, Harris BA, Decker WJ, Farquhar P: Analysis of methotrexate in human plasma by high performance liquid chromatography with fluorescence detection. Cancer Res 1977;37:3970-3973.
25. Wilson JF, Tsanaclis LM, Barnett K: External quality assessment of Syva Emit and Abbott TDx II assays for methotrexate in serum. Ther Drug Monit 1996; 18:721-723.
26. Yu Z, Westerlund D, Boos K-S: Determination of methotrexate and its metabolite 7-hydroxymethotrexate by direct injection of human plasma into a column-switching liquid chromatographic system using post-column photochemical reaction with fluorimetric detection. J Chromatography B 1997;689:379-386.
27. Keller H: Klinisch-chemische Labordiagnostik für die Praxis Stuttgart, Thieme 1991, pp 73.